JP2023516630A5 - - Google Patents
Info
- Publication number
- JP2023516630A5 JP2023516630A5 JP2022551825A JP2022551825A JP2023516630A5 JP 2023516630 A5 JP2023516630 A5 JP 2023516630A5 JP 2022551825 A JP2022551825 A JP 2022551825A JP 2022551825 A JP2022551825 A JP 2022551825A JP 2023516630 A5 JP2023516630 A5 JP 2023516630A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025203938A JP2026035711A (ja) | 2020-02-27 | 2025-11-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2002786.8A GB202002786D0 (en) | 2020-02-27 | 2020-02-27 | Liquid pharmaceutical composition |
| GB2002786.8 | 2020-02-27 | ||
| PCT/GB2021/050496 WO2021171034A1 (en) | 2020-02-27 | 2021-02-26 | Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203938A Division JP2026035711A (ja) | 2020-02-27 | 2025-11-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023516630A JP2023516630A (ja) | 2023-04-20 |
| JP2023516630A5 true JP2023516630A5 (https=) | 2024-02-29 |
| JPWO2021171034A5 JPWO2021171034A5 (https=) | 2024-02-29 |
| JP7781762B2 JP7781762B2 (ja) | 2025-12-08 |
Family
ID=70278709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551825A Active JP7781762B2 (ja) | 2020-02-27 | 2021-02-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
| JP2025203938A Pending JP2026035711A (ja) | 2020-02-27 | 2025-11-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203938A Pending JP2026035711A (ja) | 2020-02-27 | 2025-11-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20230112220A1 (https=) |
| EP (2) | EP4110292B1 (https=) |
| JP (2) | JP7781762B2 (https=) |
| KR (1) | KR20220149669A (https=) |
| CN (1) | CN115279343A (https=) |
| AU (1) | AU2021227456A1 (https=) |
| BR (1) | BR112022016015A2 (https=) |
| CA (1) | CA3166952A1 (https=) |
| DK (1) | DK4110292T3 (https=) |
| ES (1) | ES2970571T3 (https=) |
| FI (1) | FI4110292T3 (https=) |
| GB (1) | GB202002786D0 (https=) |
| HR (1) | HRP20240288T1 (https=) |
| HU (1) | HUE065531T2 (https=) |
| IL (1) | IL295442A (https=) |
| LT (1) | LT4110292T (https=) |
| MX (1) | MX2022010014A (https=) |
| PH (1) | PH12022552278A1 (https=) |
| PL (1) | PL4110292T3 (https=) |
| PT (1) | PT4110292T (https=) |
| RS (1) | RS65330B1 (https=) |
| SI (1) | SI4110292T1 (https=) |
| SM (1) | SMT202400076T1 (https=) |
| WO (1) | WO2021171034A1 (https=) |
| ZA (1) | ZA202208763B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3142701T3 (en) | 2014-05-12 | 2018-08-13 | Verona Pharma Plc | New treatment |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| WO2024088364A1 (zh) * | 2022-10-28 | 2024-05-02 | 江苏恒瑞医药股份有限公司 | 一种包含异喹啉酮类化合物的药物组合物及其制备方法 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| CN121620356A (zh) | 2023-06-26 | 2026-03-06 | 维罗纳制药公司 | 包含恩塞芬汀的颗粒组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2208310T3 (es) | 1999-03-31 | 2004-06-16 | Vernalis Limited | Derivados de pirimido(6,1-a) isoquinolin-4-ona. |
| GB2468073B (en) * | 2008-02-26 | 2012-09-05 | Elevation Pharmaceuticals Inc | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2968313B1 (en) | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
| CN110051627A (zh) * | 2014-09-15 | 2019-07-26 | 维罗纳制药公司 | 包含rpl554的液体吸入制剂 |
-
2020
- 2020-02-27 GB GBGB2002786.8A patent/GB202002786D0/en not_active Ceased
-
2021
- 2021-02-26 WO PCT/GB2021/050496 patent/WO2021171034A1/en not_active Ceased
- 2021-02-26 MX MX2022010014A patent/MX2022010014A/es unknown
- 2021-02-26 PL PL21709782.3T patent/PL4110292T3/pl unknown
- 2021-02-26 EP EP21709782.3A patent/EP4110292B1/en active Active
- 2021-02-26 PH PH1/2022/552278A patent/PH12022552278A1/en unknown
- 2021-02-26 DK DK21709782.3T patent/DK4110292T3/da active
- 2021-02-26 RS RS20240350A patent/RS65330B1/sr unknown
- 2021-02-26 SI SI202130101T patent/SI4110292T1/sl unknown
- 2021-02-26 SM SM20240076T patent/SMT202400076T1/it unknown
- 2021-02-26 BR BR112022016015A patent/BR112022016015A2/pt unknown
- 2021-02-26 HR HRP20240288TT patent/HRP20240288T1/hr unknown
- 2021-02-26 KR KR1020227029927A patent/KR20220149669A/ko active Pending
- 2021-02-26 CA CA3166952A patent/CA3166952A1/en active Pending
- 2021-02-26 US US17/904,816 patent/US20230112220A1/en active Pending
- 2021-02-26 JP JP2022551825A patent/JP7781762B2/ja active Active
- 2021-02-26 ES ES21709782T patent/ES2970571T3/es active Active
- 2021-02-26 FI FIEP21709782.3T patent/FI4110292T3/fi active
- 2021-02-26 CN CN202180016396.7A patent/CN115279343A/zh active Pending
- 2021-02-26 AU AU2021227456A patent/AU2021227456A1/en active Pending
- 2021-02-26 LT LTEPPCT/GB2021/050496T patent/LT4110292T/lt unknown
- 2021-02-26 IL IL295442A patent/IL295442A/en unknown
- 2021-02-26 PT PT217097823T patent/PT4110292T/pt unknown
- 2021-02-26 HU HUE21709782A patent/HUE065531T2/hu unknown
- 2021-02-26 EP EP23213674.7A patent/EP4306129A3/en active Pending
-
2022
- 2022-08-04 ZA ZA2022/08763A patent/ZA202208763B/en unknown
-
2025
- 2025-11-26 JP JP2025203938A patent/JP2026035711A/ja active Pending